Effectiveness for remission maintenance rate and safety of different rituximab regimens for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan: a J-CANVAS study.
Ogita C, Noguchi K, Takeuchi J, Azuma N, Omura S, Nakagomi D, Abe Y, Kadoya M, Takizawa N, Nomura A, Kukida Y, Kondo N, Yamano Y, Yanagida T, Endo K, Hirata S, Takeuchi T, Ichinose K, Kato M, Yanai R, Matsuo Y, Shimojima Y, Nishioka R, Okazaki R, Takata T, Ito T, Moriyama M, Takatani A, Miyawaki Y, Kawahito Y, Ito-Ihara T, Kida T, Yajima N, Kawaguchi T, Matsui K.
Ogita C, et al. Among authors: kawaguchi t.
Immunol Med. 2025 Jan 11:1-8. doi: 10.1080/25785826.2024.2448912. Online ahead of print.
Immunol Med. 2025.
PMID: 39797708